Factors Influencing Liver Transplant Length of Stay at Two Large-Volume Transplant Centers

Transplant Center, University of Texas Health Science Center, San Antonio, TX, USA.
Liver Transplantation (Impact Factor: 3.79). 11/2009; 15(11):1570-8. DOI: 10.1002/lt.21858
Source: PubMed

ABSTRACT Length of stay (LOS) is considered a reliable surrogate for liver transplant resource utilization. Little information exists about how donor and recipient variables interact to affect transplant LOS. Data for adult, non-status 1 transplants (1998-2005), including the donor risk index (DRI) and Model for End-Stage Liver Disease (MELD) scores, were collected from 2 institutions (n = 745 for center A and n = 710 for center B). Cox proportional hazards models identified variables associated with LOS for the separate and combined cohorts. The cohorts differed significantly in donor, recipient, and transplant factors. DRI (1.46 for center A and 1.40 for center B, P = 0.0013) and MELD (22.4 for center A and 20.4 for center B, P = 0.046) were both higher at center A, but LOS was comparable (13.7 days for center A and 13.3 days for center B, P = 0.052). Three factors at center A (nonlocal donor, recipient age, and MELD) and 7 factors at center B (donor age and weight, recipient female gender, retransplant status, international normalized ratio, MELD, and cold ischemia time) were associated with transplant LOS. For the combined cohort, donor age, weight, nonlocal status, recipient age, female gender, retransplant status, MELD, and transplant center were LOS risk factors. In conclusion, the impact of donor and recipient variables on LOS varies by institution. However, the MELD score exerts a potent and consistent effect across institutions, emphasizing the dominant role of disease severity in liver transplant resource utilization.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Decreases in endothelial nitric oxide synthase derived nitric oxide (NO) production during liver transplantation promotes injury. We hypothesized that preemptive inhaled NO (iNO) would improve allograft function (primary) and reduce complications post-transplantation (secondary). Patients at two university centers (Center A and B) were randomized to receive placebo (n = 20/center) or iNO (80 ppm, n = 20/center) during the operative phase of liver transplantation. Data were analyzed at set intervals for up to 9-months post-transplantation and compared between groups. Patient characteristics and outcomes were examined with the Mann-Whitney U test, Student t-test, logistic regression, repeated measures ANOVA, and Cox proportional hazards models. Combined and site stratified analyses were performed. MELD scores were significantly higher at Center B (22.5 vs. 19.5, p<0.0001), surgical times were greater at Center B (7.7 vs. 4.5 hrs, p<0.001) and warm ischemia times were greater at Center B (95.4 vs. 69.7 min, p<0.0001). No adverse metabolic or hematologic effects from iNO occurred. iNO enhanced allograft function indexed by liver function tests (Center B, p<0.05; and p<0.03 for ALT with center data combined) and reduced complications at 9-months (Center A and B, p = 0.0062, OR = 0.15, 95% CI (0.04, 0.59)). ICU (p = 0.47) and hospital length of stay (p = 0.49) were not decreased. iNO increased concentrations of nitrate (p<0.001), nitrite (p<0.001) and nitrosylhemoglobin (p<0.001), with nitrite being postulated as a protective mechanism. Mean costs of iNO were $1,020 per transplant. iNO was safe and improved allograft function at one center and trended toward improving allograft function at the other. with registry number 00582010 and the following URL:
    PLoS ONE 02/2014; 9(2):e86053. DOI:10.1371/journal.pone.0086053 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Liver transplantation is a standard of care for treatment of end-stage liver disease. The aim of this study was to evaluate resource utilization for patients admitted to the U.S. hospitals for liver transplantation from 2005 to 2009. Nationwide inpatient sample was used. A total of 5527 hospital admissions were included to the study cohort approximating 27,350 procedures nationwide (compared with 32,228 reported by United Network for Organ Sharing). Approximately 75% of patients had major or extreme severity of illness (All Patient Refined Diagnosis-Related Groups). The most prevalent comorbidities were coagulopathy (36.0%), fluid and electrolyte disorders (39.8%), anemia (18.7%), and type 2 diabetes (23.8%). Furthermore, 5.1% patients died in the hospital, 80.0% were discharged routinely or to home healthcare, and 14.9% were transferred to other healthcare facilities. The mean number of inpatient procedures was 7.2, and 3.5 were minimal therapeutic. The mean length of hospitalization was 22.2 days, the mean hospital charges were $358,200, and the mean inpatient costs of liver transplantation were $114,300. In multivariate analysis, the most significant factors associated with longer stay were younger age, major or extreme severity of illness, and more procedures performed during hospitalization. Similar factors were also associated with higher cost of inpatient treatment. Inpatient mortality, however, was associated only with more severe illness and more procedures while being inversely associated with younger age and higher income. Liver transplantation is a life-saving procedure with significant economic burden to our society. Severity of illness is the common driver of both in hospital mortality and resource utilization.
    Transplantation 09/2013; 97(1). DOI:10.1097/TP.0b013e3182a716ac · 3.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context-Organ transplant centers are under increasing scrutiny to maintain outcomes while controlling cost in a challenging population of patients. Throughout health care and transplant specifically, length of stay is used as a benchmark for both quality and resource utilization.Objective-To decrease our length of stay for liver transplant by using Lean Six Sigma methods.Design-The Six Sigma DMAIC (Define, Measure, Analyze, Improve, Control) method was used to systematically analyze our process from transplant listing to hospital discharge after transplant, identifying many factors affecting length of stay.Patients or Other Participants-Adult, single-organ, primary liver transplant recipients between July 2008 and June 2012 were included in the study. Recipients with living donors or fulminant liver failure were excluded.Intervention(s)-Multiple interventions, including a clinical pathway and enhanced communication, were implemented.Main Outcome Measure(s)-Length of stay after liver transplant and readmission after liver transplant.Results-Median length of stay decreased significantly from 11 days before the intervention to 8 days after the intervention. Readmission rate did not change throughout the study. The improved length of stay was maintained for 24 months after the study.Conclusion-Using a Lean Six Sigma approach, we were able to significantly decrease the length of stay of liver transplant patients. These results brought our center's outcomes in accordance with our goal and industry benchmark of 8 days. Clear expectations, improved teamwork, and a multidisciplinary clinical pathway were key elements in achieving and maintaining these gains.
    Progress in transplantation (Aliso Viejo, Calif.) 12/2013; 23(4):350-64. DOI:10.7182/pit2013226 · 0.69 Impact Factor